In this review, 100 diverse chemical derivatives were either designed, synthesized or naturally screened and tested as Hsp90 inhibitors, miscellaneous derivatives were synthesized that represent different scaffolds. Anti-Hsp90 activities of these compounds were examined and diverse activities were observed. Although Hsp90 inhibition had activities against cancerous cell line, there is no Hsp90 inhibitor as anticancer FDA approved drug yet, however some clinically investigated Hsp90 inhibitors are in phase I and phase II. Hsp90 inhibitors could act as a new strategy for treatment of cancer as a chronic disease rather than using typically aggressive chemotherapeutic agents.
Select your language of interest to view the total content in your interested language
Der Pharma Chemica received 15261 citations as per Google Scholar report